Orphanet: Pesquisa simples

Pesquisar um ensaio clínico

Outras opções de pesquisa

126 Resultado(s)

Ensaio (s) clínico (s) nacional (is)

Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease Institution: Information not provided - DE

BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - DE Universitätsklinikum Köln Zentrum für Palliativmedizin

BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE University College Dublin UCD School of Medicine

BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IT Institution: Information not provided - IT

APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial) Addenbrooke's Hospital Addenbrookes Hospital

RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease National Heart and Lung Institute, Imperial College, Royal Brompton Campus Interstitial Lung Disease Unit

Prospective Assessment of MRI for Morphological and Functional Imaging in the Thorax Universitätsspital Zürich Institut für diagnostische und interventionelle Radiologie

IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE- Thoraxklinik-Heidelberg gGmbH Abteilung für Pneumologie und Beatmungsmedizin

IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE- Asklepios-Fachkliniken München-Gauting Klinik für Pneumologie

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -DE Institution: Information not provided - DE

IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE- Universitätsklinikum Essen

IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE- Universitätsklinikum Schleswig-Holstein - Campus Lübeck Medizinische Klinik III - Pneumologie

Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2) Institution: Information not provided - AT

SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - AT Institution: Information not provided - AT

EXODUS: Extracorporeal Lung Assist Device in Acute Lung Impairment: A Randomized Controlled Study - AT Allgemeines Krankenhaus der Stadt Wien Intensivstation 13.i2

DeVENT: Decision Support System to Evaluate VENTilation in ARDS (acute respiratory distress syndrome) - AT Allgemeines Krankenhaus der Stadt Wien Intensivstation 13.i2

COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial (phase 2) Allgemeines Krankenhaus der Stadt Wien Universitätsklinik für klinische Pharmakologie

Noninvasive Vagal Nerve Stimulation in Patients With COVID-19 and ARDS for the Reduction of Respiratory, Hemodynamic and Neuropsychiatric Complications SMZ Süd - Kaiser-Franz-Josef-Spital 4. Medizinische Abteilung mit Infektions- und Tropenmedizin

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Service de Pneumologie

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Service de Pneumologie

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - BE Cliniques universitaires Saint-Luc - UCLouvain Service de pneumologie

A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury Mount Sinai Hospital

LORALAM-2020: Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM) - ES Hospital Universitari de Bellvitge Servicio de Neumología

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -ES Hospital Universitari de Bellvitge Servicio de Neumología

SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial -ES Institution: Information not provided - ES

Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis Institution: Information not provided - US

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI- Turku University Hospital Turku PET CENTRE

SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis CHU de Rennes - Hôpital Pontchaillou Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire

EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III) Institution: Information not provided - FR

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - FR Institution: Information not provided - FR

EIT-ECMO: Ultra-protective Ventilation Monitored by Electrical Impedance Tomography in Patients With Severe Acute Respiratory Distress Syndrome on Veno-venous ECMO Institution: Information not provided - FR

ProCoCo: Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome CHU de Marseille - Hôpital Nord Service de réanimation médicale détresses respiratoires - Infections sévères

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -IE St. Vincent's University Hospital

Individualized Positive End-expiRatory Pressure Guided by End-Expiratory Lung Volume in Moderate-to-severe Acute resPiratory Distress Syndrome.The IPERPEEP Study Institution: Information not provided - IT

Effects of Positive End-expiratory Pressure With and Without Inspiratory Synchronization During Moderate to Severe ARDS Fondazione Policlinico Universitario Agostino Gemelli IRCCS U.O.C. Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - IT Fondazione IRCCS Policlinico San Matteo

Pulmonary alveolar proteinosis GM-CSF inhalation efficacy trial in Japan Institution: Information not provided - JP

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -JP Institution: Information not provided - JP

ONE-BRIDGE: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis Saiseikai Kumamoto Hospital Respiratory Medicine & Surgery

IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study Amsterdam UMC, locatie AMC Afdeling Neurologie

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -NL St. Antonius Ziekenhuis

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -PL Institution: Information not provided - PL

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -PT Institution: Information not provided - PT

Decision Support System to Evaluate VENTilation in ARDS (DeVENT) Imperial College London, main campus Imperial College London Headquarters

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -RO Institution: Information not provided - RO

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -TR Institution: Information not provided - TR

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) -DE- Thoraxklinik-Heidelberg gGmbH Abteilung für Pneumologie und Beatmungsmedizin

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE Thoraxklinik-Heidelberg gGmbH Thoraxklinik Heidelberg

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) -DE- Lungenfachklinik Immenhausen Zentrum für Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE Universitätsklinikum Essen

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) -DE- Universitätsmedizin Essen - Ruhrlandklinik Klinik für Pneumologie

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) -DE Universitätsmedizin Essen - Ruhrlandklinik Klinik für Pneumologie

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE Universitätsklinikum Münster

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - AT Medizinische Universität Graz Klinische Abteilung für Pulmonologie

A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - AT Institution: Information not provided - AT

STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - AT Institution: Information not provided - AT

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis - AT Institution: Information not provided - AT

FIBRONEER-IPF: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) - AT Institution: Information not provided - AT

HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie

STARSCAPE: A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Service de Pneumologie

STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Service de Pneumologie

BI 1305-0014: A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF) - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Service de Pneumologie

INTEGRIS-IPF: A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis - BE Cliniques universitaires Saint-Luc - UCLouvain Service de pneumologie

A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - ES Institution: Information not provided - ES

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) -ES Institution: Information not provided - ES

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - ES Institution: Information not provided - ES

STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - ES Institution: Information not provided - ES

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis -ES Institution: Information not provided - ES

TETON-2: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis -ES Institution: Information not provided - ES

A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis -ES Institution: Information not provided - ES

FIBRONEER-IPF: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) -ES Institution: Information not provided - ES

A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis - FR Institution: Information not provided - FR

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)-FR Institution: Information not provided - FR

A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 18 mg taken orally b.i.d. -FR Institution: Information not provided - FR

A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis -FR Institution: Information not provided - FR

EXCHANGE-IPF: Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulins for Severe Acute Exacerbation of Idiopathic Pulmonary Fibrosis Admitted in ICU: an Open, Randomized, Controlled Trial. CHU Paris Nord-Val de Seine - Hôpital Xavier Bichat-Claude Bernard Service de pneumologie A

Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease
Institution: Information not provided - DE

BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - DE
Universitätsklinikum Köln

Zentrum für Palliativmedizin

BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE
University College Dublin

UCD School of Medicine

BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IT
Institution: Information not provided - IT

APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial)
Addenbrooke's Hospital

Addenbrookes Hospital

RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus

Interstitial Lung Disease Unit

Prospective Assessment of MRI for Morphological and Functional Imaging in the Thorax
Universitätsspital Zürich

Institut für diagnostische und interventionelle Radiologie

IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE-
Thoraxklinik-Heidelberg gGmbH

Abteilung für Pneumologie und Beatmungsmedizin

IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE-
Asklepios-Fachkliniken München-Gauting

Klinik für Pneumologie

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -DE
Institution: Information not provided - DE

IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE-
Universitätsklinikum Essen

IMPALA-X: An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients -DE-
Universitätsklinikum Schleswig-Holstein - Campus Lübeck

Medizinische Klinik III - Pneumologie

Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis (phase 2)
Institution: Information not provided - AT

SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial - AT
Institution: Information not provided - AT

EXODUS: Extracorporeal Lung Assist Device in Acute Lung Impairment: A Randomized Controlled Study - AT
Allgemeines Krankenhaus der Stadt Wien

Intensivstation 13.i2

DeVENT: Decision Support System to Evaluate VENTilation in ARDS (acute respiratory distress syndrome) - AT
Allgemeines Krankenhaus der Stadt Wien

Intensivstation 13.i2

COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial (phase 2)
Allgemeines Krankenhaus der Stadt Wien

Universitätsklinik für klinische Pharmakologie

Noninvasive Vagal Nerve Stimulation in Patients With COVID-19 and ARDS for the Reduction of Respiratory, Hemodynamic and Neuropsychiatric Complications
SMZ Süd - Kaiser-Franz-Josef-Spital

4. Medizinische Abteilung mit Infektions- und Tropenmedizin

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Service de Pneumologie

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Service de Pneumologie

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - BE
Cliniques universitaires Saint-Luc - UCLouvain

Service de pneumologie

A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury
Mount Sinai Hospital

LORALAM-2020: Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM) - ES
Hospital Universitari de Bellvitge

Servicio de Neumología

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -ES
Hospital Universitari de Bellvitge

Servicio de Neumología

SEAL: Safety and Efficacy of Inhaled Pegylated Adrenomedullin (PEG-ADM) in Patients Suffering From Acute Respiratory Distress Syndrome (ARDS): a Double-blind, Randomized, Placebo-controlled, Multicenter Phase 2a/b Clinical Trial -ES
Institution: Information not provided - ES

Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Institution: Information not provided - US

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI-
Turku University Hospital

Turku PET CENTRE

SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
CHU de Rennes - Hôpital Pontchaillou

Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire

EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - FR
Institution: Information not provided - FR

EIT-ECMO: Ultra-protective Ventilation Monitored by Electrical Impedance Tomography in Patients With Severe Acute Respiratory Distress Syndrome on Veno-venous ECMO
Institution: Information not provided - FR

ProCoCo: Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome
CHU de Marseille - Hôpital Nord

Service de réanimation médicale détresses respiratoires - Infections sévères

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -IE
St. Vincent's University Hospital

Individualized Positive End-expiRatory Pressure Guided by End-Expiratory Lung Volume in Moderate-to-severe Acute resPiratory Distress Syndrome.The IPERPEEP Study
Institution: Information not provided - IT

Effects of Positive End-expiratory Pressure With and Without Inspiratory Synchronization During Moderate to Severe ARDS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

U.O.C. Anestesia, Rianimazione, Terapia Intensiva e Tossicologia Clinica

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - IT
Fondazione IRCCS Policlinico San Matteo

Pulmonary alveolar proteinosis GM-CSF inhalation efficacy trial in Japan
Institution: Information not provided - JP

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -JP
Institution: Information not provided - JP

ONE-BRIDGE: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis
Saiseikai Kumamoto Hospital

Respiratory Medicine & Surgery

IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study
Amsterdam UMC, locatie AMC

Afdeling Neurologie

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -NL
St. Antonius Ziekenhuis

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -PL
Institution: Information not provided - PL

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -PT
Institution: Information not provided - PT

Decision Support System to Evaluate VENTilation in ARDS (DeVENT)
Imperial College London, main campus

Imperial College London Headquarters

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -RO
Institution: Information not provided - RO

IMPALA-2: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) -TR
Institution: Information not provided - TR

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) -DE-
Thoraxklinik-Heidelberg gGmbH

Abteilung für Pneumologie und Beatmungsmedizin

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE
Thoraxklinik-Heidelberg gGmbH

Thoraxklinik Heidelberg

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE
Universitätsklinikum Essen

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) -DE-
Universitätsmedizin Essen - Ruhrlandklinik

Klinik für Pneumologie

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) -DE
Universitätsmedizin Essen - Ruhrlandklinik

Klinik für Pneumologie

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - DE
Universitätsklinikum Münster

A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally (Phase 2) - AT
Medizinische Universität Graz

Klinische Abteilung für Pulmonologie

A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - AT
Institution: Information not provided - AT

STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - AT
Institution: Information not provided - AT

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis - AT
Institution: Information not provided - AT

FIBRONEER-IPF: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) - AT
Institution: Information not provided - AT

HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie

STARSCAPE: A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Service de Pneumologie

STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Service de Pneumologie

BI 1305-0014: A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Service de Pneumologie

INTEGRIS-IPF: A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis - BE
Cliniques universitaires Saint-Luc - UCLouvain

Service de pneumologie

A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis - ES
Institution: Information not provided - ES

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF) -ES
Institution: Information not provided - ES

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - ES
Institution: Information not provided - ES

STARSCAPE-OLE: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) - ES
Institution: Information not provided - ES

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis -ES
Institution: Information not provided - ES

TETON-2: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis -ES
Institution: Information not provided - ES

A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis -ES
Institution: Information not provided - ES

FIBRONEER-IPF: A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) -ES
Institution: Information not provided - ES

A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis - FR
Institution: Information not provided - FR

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)-FR
Institution: Information not provided - FR

A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 18 mg taken orally b.i.d. -FR
Institution: Information not provided - FR

A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis -FR
Institution: Information not provided - FR

EXCHANGE-IPF: Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulins for Severe Acute Exacerbation of Idiopathic Pulmonary Fibrosis Admitted in ICU: an Open, Randomized, Controlled Trial.
CHU Paris Nord-Val de Seine - Hôpital Xavier Bichat-Claude Bernard

Service de pneumologie A

EXAFIP : Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial (Phase III)
Groupe hospitalier AP-HP.6 - Hôpital Tenon

Unité Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis - IE
St. Vincent's University Hospital

CF Clinic

A multi-cohort, randomised, placebo-controlled Phase IIa study to assess the safety, pharmacokinetics, pharmacodynamics and clinical activity of ascending doses of RXC007 in patients with idiopathic pulmonary fibrosis - IT
Institution: Information not provided - IT

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
CWZ - Canisius Wilhelmina Ziekenhuis

Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) - NL
Zuyderland Medisch Centrum, locatie Heerlen